Unknown

Dataset Information

0

Endoplasmic reticulum stress promotes sorafenib resistance via miR-188-5p/hnRNPA2B1-mediated upregulation of PKM2 in hepatocellular carcinoma


ABSTRACT: Emerging evidence has shown that endoplasmic reticulum (ER) stress promotes sorafenib resistance in hepatocellular carcinoma (HCC). However, the underlying mechanisms are poorly understood. The purpose of this study was to explore the mechanism by which ER stress promotes sorafenib resistance in HCC. We found that pyruvate kinase isoform M2 (PKM2) was highly expressed in human HCC tissues and co-related with worse clinicopathologic features and overall survival. Activation of ER stress positively correlated with PKM2 expression both in HCC tissue samples and tunicamycin (TM)-induced HCC cell lines. PKM2 knockdown increased sorafenib-induced apoptosis and decreased the ability of colony formation, while upregulation of PKM2 reverses this phenomenon. Furthermore, high-throughput sequencing identified that activation of ER stress significantly downregulated the expression of miR-188-5p in HCC cells. According to bioinformatics analysis and dual-luciferase assays, we further confirmed that hnRNPA2B1 is the target gene of miR-188-5p. Downregulating the expression of hnRNPA2B1 with siRNA could decrease the expression of PKM2 and enhance sorafenib-induced apoptosis in HepG2 cells. Our study demonstrated that ER stress could promote sorafenib resistance through upregulating PKM2 via miR-188-5p/hnRNPA2B1. Therefore, targeting the miR-188-5p/hnRNPA2B1/PKM2 pathway and ER stress may prove instrumental in overcoming sorafenib resistance in HCC treatment. Graphical abstract The underlying mechanisms of endoplasmic reticulum (ER) stress that promote sorafenib resistance in hepatocellular carcinoma (HCC) are poorly understood. This study demonstrated that ER stress could promote sorafenib resistance by upregulating PKM2 via miR-188-5p/hnRNPA2B1. Therefore, targeting the miR-188-5p/hnRNPA2B1/PKM2 pathway and ER stress may prove instrumental in overcoming sorafenib resistance in HCC treatment.

SUBMITTER: Zhou B 

PROVIDER: S-EPMC8569435 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6511640 | biostudies-literature
| S-EPMC7256049 | biostudies-literature
| S-EPMC4599266 | biostudies-literature
| S-EPMC3787795 | biostudies-literature
| S-EPMC7584607 | biostudies-literature
| S-EPMC4575108 | biostudies-literature
| S-EPMC9454520 | biostudies-literature
| S-EPMC7419617 | biostudies-literature
| S-EPMC8658035 | biostudies-literature
| S-EPMC8100964 | biostudies-literature